Abstracts tagged "etanercept"

Abstract Number: 631 • 2016 ACR/ARHP Annual Meeting
Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
Alfredomaria Lurati¹, Magda Scarpellini², Katia Angela re³, Mariagrazia Marrazza³, Daniela Mazzocchi³ and Antonella Laria⁴, ¹Fornaroli Hospital Rheumatology Unit Magenta Italy, Magenta, Italy, ²Rheumatology Unit, Ospedale Fornaroli, Magenta, Italy, ³Fornaroli Hospital, Rheumatology Unit, MAgenta, Italy, ⁴Fornaroli Hospital, Rheumatology Unit, Magenta, Italy
Biologic free remission rate with etanercept in rheumatoid arthritis: a potential role of gender A.M. Lurati and A. Laria, D. Mazzocchi, K.A. Re, M. Marrazza,…
Abstract Number: 642 • 2016 ACR/ARHP Annual Meeting
Quality of Life Outcomes Following Therapy with Chs-0214 and Etanercept (Enbrel): Randomized, Double-Blind Study in Subjects with Rheumatoid Arthritis
Alan J. Kivitz^1,2, James R. O'Dell³, Tsutomu Takeuchi⁴, Yoshiya Tanaka⁵, Satoshi Nakashima⁶, Cass Kelleher⁷, Jennifer Hodge⁸, Barbara Finck⁷ and RApsody Study Group, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ³Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ⁵The First Department of Internal Medicine,, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁶Daiishi Sankyo, Shinagawa-Ku Tokyo, Japan, ⁷Clinical Science, Coherus BioSciences, Redwood City, CA, ⁸Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is in development as a proposed biosimilar of etanercept. This Phase III confirmatory, safety and efficacy study randomized and dosed 644 subjects with…
Abstract Number: 736 • 2016 ACR/ARHP Annual Meeting
A Multi-Center, Open Label, Randomized Clinical Tries of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Ankylosing Spondylitis
Jieruo Gu¹, Liudan Tu², Minjing Zhao³, Zhiming Lin⁴, Zetao Liao⁵, Shuangyan Cao⁶, Qinghong Yu⁷ and Zhizhong Ye⁸, ¹Rheumatology, Third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ²The Third Hospital of Sun Yat-sen University, Guangzhou, China, ³The Third Affiliated Hospital of Sun Yat-sen University, guangzhou, China, ⁴Rheumatology, 3rd Affiliated Hospital of Sun Yat-Sen Uni, Guangzhou, China, ⁵Rheumatology, 3rd Affiliated Hoapital of Sun Yat-Sen Uni, Guangzhou, China, ⁶Rheumatology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, ⁷Department of Rheumatology, Fourth People’s Hospital of Shenzhen City, Xiangmi Lake branch, Guangzhou, China, ⁸Department of Rheumatology，ZhuJiang Hospital of Southern Medical University, Guangzhou, China
Background/Purpose: To compare the clinical、radiographic and magnatic resonance imaging change in active ankylosing spondylitis patients with etanercept and celecoxib alone/combined treatment，and to evaluate the effectiveness…
Abstract Number: 1101 • 2016 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Induce a Divergent Proteomic Profile in Human Osteoclast Precursors to That Resembling a Monocytic Cell
Bohdan P. Harvey¹, Chenqi Hu², Dongdong Wang², Yu Tian² and Zehra Kaymakcalan¹, ¹Global Biologics, AbbVie Bioresearch Center, Worcester, MA, ²DMPK-BA, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast (OC) development.…
Abstract Number: 1709 • 2016 ACR/ARHP Annual Meeting
Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept (Enbrel) in Patients with Psoriasis and Psoriatic Arthritis
Alan J. Kivitz¹, Kim Papp², Alim Devani³, Andreas Pinter⁴, Rodney Sinclair^5,6,7, Michael Ziv⁸, John Caminis⁹, Cass Kelleher¹⁰, Helen Tang¹¹, Barbara Finck¹⁰ and RaPsOdy study group , ¹Altoona Center for Clinical Research, Duncansville, PA, ²K Papp Clinical Research, Inc. and Probity Medical Research, Waterloo, ON, Canada, ³Institute for Skin Advancement, Surgical and Cosmetic Dermatology, Calgary, AB, Canada, ⁴Dept. of Dermatology, Venereology and Allergology, Theodor-Stern-Kai 7, Frankfurt, Germany, ⁵University of Melbourne, E. Melbourne, Australia, ⁶Epworth Healthcare, E. Melbourne, Australia, ⁷Sinclair Dermatology Investigational Research, Education and Clinical Trials, E. Melbourne, Australia, ⁸Dept of Dermatology, Emek Medical Center, Afula, Israel, ⁹Shire, cambridge, MA, ¹⁰Clinical Science, Coherus BioSciences, Redwood City, CA, ¹¹Coherus BioSciences, Redwood City, CA
Background/Purpose: CHS-0214 is a proposed biosimilar of etanercept, a fusion protein inhibiting tumor necrosis factor. This Phase III multi-center study compared the efficacy and safety…
Abstract Number: 2231 • 2016 ACR/ARHP Annual Meeting
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld^2,3, Eunice Chang⁴, Elya Papoyan⁴ and Michael S. Broder⁴, ¹Center for Observational Research, Amgen, Inc, Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Amgen Inc., Thousand Oaks, CA, ⁴Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of…
Abstract Number: 2472 • 2016 ACR/ARHP Annual Meeting
Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort
Ana C.M. Ribeiro¹, Karina Bonfiglioli², Renata Miossi², Carla G.S. Saad¹, Julio C. B. Moraes³, Mariana G Waisberg¹, Fernando Henrique Carlos de Souza¹, Nadia E Aikawa⁴, Leandro L. do Prado¹, Michelle Lopes¹, Luciana Seguro¹ and Eloisa Bonfá³, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Predictors of rheumatoid arthritis (RA) response to anti-TNF agents have been described. Except for certolizumab, the value of interim analysis before 24 weeks of…
Abstract Number: 2482 • 2016 ACR/ARHP Annual Meeting
Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
I.M Visman¹, MJ l'Ami², Gertjan Wolbink³ and Mike T. Nurmohamed^4,5, ¹Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center, Reade, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Rheumatology, Reade, Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are effective, safe and widely used treatment for rheumatoid arthritis (RA). The therapy is often started in combination…
Abstract Number: 2059 • 2015 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Tapering Induced Radiographic Progression Is Driven By Weighted Mean Disease Activity over Time, Not Flaring or Lower TNFi Exposition
Alfons A. den Broeder¹, Chantal A.M. Bouman¹, Aatke van der Maas², Frank H.J. van den Hoogen¹, Noortje van Herwaarden¹ and R. Landewe³, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Hengstdal 3, Sint Maartenskliniek, Nijmegen, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, Maastricht, Netherlands
Background/Purpose: DRESS, a randomized controlled strategy trial (RCT)1investigating disease activity guided tapering of etanercept and adalimumab compared to usual care in RA patients, indicated that…
Abstract Number: 2417 • 2015 ACR/ARHP Annual Meeting
Induction and Maintenance of Remission By Etanercept in Enthesitis Related Arthritis JIA-Patients
Gerd Horneff¹, Ivan Foeldvari², Kirsten Minden³, Ralf Trauzeddel⁴, J B. Kuemmerle-Deschner⁵, Klaus Tenbrock⁶, Gerd Ganser⁷ and Hans-Iko Huppertz⁸, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ³DRFG, Berlin, Germany, ⁴HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁵Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁶University Aachen, Aachen, Germany, ⁷Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁸PRINTO, IRCCS G. Gaslini, Genoa, Italy
Background/Purpose: Enthesitis-related arthritis (ERA) is a juvenile idiopathic arthritis (JIA) category affecting entheses and joints. The REMINDER study to analyse the efficacy of etanercept (ETA)…
Abstract Number: 2419 • 2015 ACR/ARHP Annual Meeting
Safety and Efficacy of Etanercept in 2000 Patients with Juvenile Idiopathic Arthritis (JIA) in the JIA Biologics Register
Gerd Horneff¹, Juergen Brunner², Johannes Peter Haas³, Gerd Ganser⁴, Ivan Foeldvari⁵, Toni Hospach⁶, Kirsten Minden⁷, Hans-Iko Huppertz⁸, Rolf M. Kuester⁹, Ralf Trauzeddel¹⁰, Angelika Thon¹¹ and BIKER Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Universitätsklinik für Kinder- u. Jugendheilkunde, Innsbruck, Austria, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ⁵Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁶Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁷DRFG, Berlin, Germany, ⁸PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁹Asklepios Rheumazentrum Hamburg, Hamburg, Germany, ¹⁰HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ¹¹Department of Pediatrics, Hannover, Germany
Background/Purpose: Treatment with Etanercept (ETA) was followed prospectively. The purpose of this interim analysis is to evaluate efficacy/ safety of ETA in routine care settings.…
Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Nicolino Ruperto¹, Tamas Constantin², Ivan Foeldvari³, Jelena Vojinovic⁴, Gerd Horneff⁵, Rubén Burgos-Vargas⁶, Irina Nikishina⁷, Jonathan Akikusa⁸, Tadej Avcin⁹, Jeffrey Chaitow¹⁰, Elena Koskova¹¹, Bernard R. Lauwerys¹², Inmaculada Calvo-Penedes¹³, Berit Flato¹⁴, Maria Luz Gamir Gamir¹⁵, Hans-Iko Huppertz¹⁶, Juan Jose Jaller Raad¹⁷, Katerina Jarosova¹⁸, Jordi Anton¹⁹, Marie Macku²⁰, William Jose Otero Escalante²¹, Lidia Rutkowska-Sak²², Ralf Trauzeddel²³, Carine Wouters²⁴, Ronald Pedersen²⁵, Sameer Kotak²⁶, Jack F Bukowski²⁷, Tina Hinnershitz²⁸, Bonnie Vlahos²⁹ and Alberto Martini³⁰, ¹Pediatria II, PRINTO, Istituto G. Gaslini, Universita' di Genova, Genova, Italy, ²Semmelweis University, Budapest, Hungary, ³Hamburg Centre for Child and Adolescent Rheumatology, Hamburg, Germany, ⁴Faculty of Medicine, University of Nis, Nis, Serbia, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁷V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Rheumatology, Royal Children's Hospital, Melbourne, Australia, ⁹Allergology, Rheumatology and Clinical Immunology, University Medical Center Ljubljana, Ljubljana, Slovenia, ¹⁰The Sydney Children's Hospital Network, Sydney, Australia, ¹¹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹²Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹³Hospital Universitario y Piltecnico La Fe, Valencia, Spain, ¹⁴Oslo University Hospital, Oslo, Norway, ¹⁵Rheumatology, Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, ¹⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ¹⁷Centro de Reumatologia y Ortopedia, Barranquilla, Colombia, ¹⁸Revmatologicky ustav, Prague, Czech Republic, ¹⁹Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ²⁰1, Facutly Children's Hospital Brno, Brno, Czech Republic, ²¹Servimed S.A.S, Santander, Colombia, ²²Instytut Reumatologii, Klinika i Poliklinika Reumatologii Wieku Rozwojowego, Warszawa, Poland, ²³HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ²⁴UZ Leuven, Leuven, Belgium, ²⁵Department of Biostatistics, Pfizer, Collegeville, PA, ²⁶Global Health and Value, Pfizer, New York, NY, ²⁷Pfizer, Collegeville, PA, ²⁸Specialty Care MDG, Pfizer, Collegeville, PA, ²⁹GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ³⁰Istituto G. Gaslini, Universita' di Genova, Genova, Italy
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…
Abstract Number: 2692 • 2015 ACR/ARHP Annual Meeting
The Patients Evaluation of Pain and Disease Activity As Well As Improvement during One-Year Follow-up on Etanercept Treatment Is Highly Associated to Subjective Factors and Not to Objective Assessments Including Ultrasound
Hilde Berner Hammer¹ and Jon Lampa², ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Patient reported outcomes (PROs) are important for evaluation of treatment response in patients with rheumatoid arthritis (RA). Ultrasound (US) is a sensitive method for…
Abstract Number: 2747 • 2015 ACR/ARHP Annual Meeting
Study Completion and Etanercept Retention in Patients with Rheumatoid Arthritis Treated with Etanercept Monotherapy Versus Etanercept and Methotrexate Combination Therapy
Janet E. Pope¹, Edward C. Keystone², J Carter Thorne³, Melanie Poulin-Costello⁴, Krystene Phan-Chronis⁴ and Boulos Haraoui⁵, ¹University of Western Ontario, London, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Amgen Canada Inc., Mississauga, ON, Canada, ⁵University of Montreal Hospital Centre, Montreal, QC, Canada
Background/Purpose: The CAnadian Methotrexate and Etanercept Outcome (CAMEO) study, an open-label trial in patients with active rheumatoid arthritis (RA), revealed that patients achieving low disease…
Abstract Number: 2885 • 2015 ACR/ARHP Annual Meeting
Long-Term Effects of Etanercept on Patient-Reported Outcomes in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Results of a Phase III Study
Filip van Den Bosch^1,2, Edit Drescher³, Jan Rosa⁴, Ronald Pedersen⁵, Randi Bonin⁶, Bonnie Vlahos⁷, Jack F Bukowski⁶ and Sameer Kotak⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Csolnoky Ferenc Hospital, Veszprém, Hungary, ⁴Mediscan Group, Prague, Czech Republic, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁸Global Health and Value, Pfizer, New York, NY
Background/Purpose: In patients with active, NSAID-resistant, non-radiographic axial spondyloarthritis (nr-axSpA) who participated in the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), health-related quality-of-life…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.